Madrigal Pharmaceuticals (MDGL) EBT Margin (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) posted quarterly EBT Margin of 15.69% for Q2 2026, up 418.0% year-over-year from 3.03% in Q2 2025, and up 47.08% quarter-over-quarter from 29.65% in Q1 2026.
Powered by 
Analysis
Madrigal Pharmaceuticals (MDGL) EBT Margin (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has reported EBT Margin for 6 consecutive years, with 15.69% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT Margin rose 418.0% year-over-year to 15.69%; the TTM figure through Jun 2026 stood at 33.69% (up 1836.0% YoY), while the FY2025 annual figure was 89.08%, up 44387.0% from the prior year.
- EBT Margin advanced to 15.69% in Q2 2026 per MDGL's latest filing, from 29.65% in the prior quarter.
- Across five years, EBT Margin topped out at 15.69% in Q2 2026 and bottomed at 1038.2% in Q2 2024.
- Historically, EBT Margin has averaged 162.82% across 3 years, with a median of 44.37% in 2024.
- On a YoY basis, EBT Margin climbed as much as 101833 bps in 2025 and fell as far as 919 bps in 2025.
- Madrigal Pharmaceuticals' EBT Margin stood at 44.37% in 2024, then fell by 21 bps to 53.56% in 2025, then surged by 71 bps to 15.69% in 2026.
- Business Quant data shows MDGL's EBT Margin at 15.69% in Q2 2026, 29.65% in Q1 2026, and 53.56% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 12.09% |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -2.67% |
| 10 | Madrigal Pharmaceuticals | 15.81 Bn | 14.97 Bn | - | -15.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -15.69% |
| Mar 31, 2026 | -29.65% |
| Dec 31, 2025 | -18.20% |
| Sep 30, 2025 | -38.68% |
| Jun 30, 2025 | -19.87% |
| Mar 31, 2025 | -53.36% |
| Dec 31, 2024 | -57.51% |
| Sep 30, 2024 | -172.04% |
| Jun 30, 2024 | -1,038.20% |
| Sep 30, 2012 | -30,385.71% |
| Jun 30, 2012 | -20,184.35% |
| Mar 31, 2012 | -10,238.78% |
| Dec 31, 2011 | -313.85% |
| Sep 30, 2011 | -765.26% |
| Jun 30, 2011 | -923.34% |
| Mar 31, 2011 | -997.46% |
| Dec 31, 2010 | -218.55% |
| Sep 30, 2010 | -303.34% |
| Jun 30, 2010 | -270.06% |